Highlights
- The SOLTI-1507 IPATHER trial established 400 mg daily (21 days on, 7 days off) as the recommended phase 2 dose for ipatasertib when combined with trastuzumab and pertuzumab.
- The combination therapy demonstrated a manageable safety profile, with diarrhea and nausea being the most common treatment-related adverse events.
- Preliminary efficacy data are encouraging, showing a median progression-free survival of 16.4 months in a population with PIK3CA mutations, a known driver of resistance.
- The study supports the feasibility of a chemo-free maintenance strategy targeting the PI3K/AKT pathway in HER2-positive metastatic breast cancer.
Background: The Challenge of PIK3CA Mutations in HER2-Positive Disease
The management of HER2-positive (HER2+) metastatic breast cancer (MBC) has been revolutionized by the introduction of dual HER2 blockade with trastuzumab and pertuzumab (HP). While first-line induction chemotherapy combined with HP provides significant survival benefits, the subsequent maintenance phase—typically HP alone or with endocrine therapy—remains a period where resistance eventually develops. One of the most critical mechanisms of resistance to HER2-targeted agents is the hyperactivation of the PI3K/AKT/mTOR signaling pathway.
Approximately 30% to 40% of HER2+ breast cancers harbor mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K). These mutations lead to constitutive activation of downstream signaling, particularly through the serine/threonine kinase AKT. In the clinical setting, PIK3CA mutations have been associated with a lower rate of pathological complete response to neoadjuvant therapy and shorter progression-free survival (PFS) in the metastatic setting. Consequently, there is a clear unmet medical need for therapeutic strategies that can effectively inhibit this pathway and prolong the duration of response in patients with PIK3CA-mutated, HER2+ MBC.
Study Design: The SOLTI-1507 IPATHER Trial
The SOLTI-1507 IPATHER trial (NCT04253561) was a prospective, multicenter, single-arm, phase 1b study designed to evaluate the safety, feasibility, and preliminary efficacy of adding ipatasertib to maintenance HP. Ipatasertib is a potent, oral, highly selective small-molecule inhibitor of all three isoforms of AKT. By blocking AKT, researchers hypothesized that they could restore sensitivity to HER2-targeted therapy and delay disease progression.
The study population consisted of 17 patients with unresectable locally advanced or metastatic HER2+ breast cancer harboring PIK3CA mutations. All participants had previously received first-line induction chemotherapy (typically a taxane) combined with HP and had achieved at least stable disease. The intervention involved ipatasertib combined with standard doses of trastuzumab and pertuzumab, with or without endocrine therapy (ET) for those with hormone receptor-positive disease. The primary endpoint was the assessment of dose-limiting toxicities (DLTs) during the first 28-day cycle to establish the recommended phase 2 dose (RP2D).
Safety and Tolerability: Establishing the RP2D
The trial successfully established the RP2D of ipatasertib at 400 mg daily on a schedule of 21 days on followed by 7 days off. This dosing regimen was determined after the first six patients treated at this level completed the initial cycle without experiencing any DLTs. The median follow-up for the cohort was 27.7 months, providing a robust window for observing long-term safety.
Regarding the safety profile, 41.2% of patients (n=7) experienced grade 3 treatment-related adverse events (TRAEs). The most frequent adverse events were gastrointestinal in nature, specifically diarrhea and nausea, which are well-known class effects of AKT and PI3K inhibitors. Serious TRAEs were reported in two patients (11.8%) and included four distinct events: diarrhea, vomiting, ischemic stroke, and pneumonitis. Notably, all patients recovered from these serious events after appropriate medical intervention and dose modifications. The safety data suggest that while the combination requires proactive management of gastrointestinal toxicity, it is generally feasible for use in a maintenance setting.
Key Findings: Encouraging Efficacy Signals
Although the primary focus was safety, the preliminary efficacy results are particularly noteworthy given the high-risk nature of the PIK3CA-mutated population. The confirmed overall response rate (ORR) was 31.1% (95% CI: 12.1-58.5%), and the clinical benefit rate (CBR) reached a substantial 84.6% (95% CI: 53.7-97.3%).
The median progression-free survival (PFS) was 16.4 months (95% CI: 9.4-NR). Furthermore, 47.3% of patients remained progression-free at the 18-month mark. These figures are compelling when compared to historical benchmarks for maintenance therapy in PIK3CA-mutated cohorts, where PFS is often significantly shorter than in their wild-type counterparts. The data suggest that the addition of an AKT inhibitor may indeed mitigate the negative prognostic impact of PIK3CA mutations in HER2+ MBC.
Expert Commentary: Precision Medicine in Maintenance Therapy
The IPATHER trial represents a significant step toward personalized maintenance therapy in HER2+ MBC. By selecting patients based on the presence of a PIK3CA mutation, the study targets the specific biological driver of resistance. Historically, the treatment of HER2+ disease has been somewhat uniform, but as our understanding of molecular heterogeneity grows, the move toward such biomarker-driven approaches is essential.
One of the strengths of this study is its focus on the maintenance phase. Many patients find it difficult to tolerate long-term chemotherapy, and a chemo-free maintenance regimen that combines biological blockade (HP) with pathway-specific inhibition (ipatasertib) offers an attractive alternative. However, the study is not without limitations. As a single-arm phase 1b trial with a small sample size (n=17), the efficacy data must be interpreted with caution. The lack of a control group makes it difficult to definitively attribute the prolonged PFS solely to ipatasertib. Furthermore, the gastrointestinal toxicity, while manageable, requires clinicians to be vigilant and employ early anti-diarrheal interventions.
Mechanistically, the success of ipatasertib in this trial aligns with the broader understanding of the crosstalk between the HER2 and PI3K/AKT pathways. When HER2 is inhibited by HP, the cell often seeks alternative survival signals; in the presence of a PIK3CA mutation, the AKT pathway provides a ready-made escape route. Simultaneous inhibition of both HER2 and AKT effectively “shuts the back door,” leading to more durable tumor suppression.
Conclusion and Future Directions
The SOLTI-1507 IPATHER trial concludes that the combination of ipatasertib plus trastuzumab and pertuzumab is a safe and promising maintenance strategy for patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations. The identification of the RP2D and the encouraging PFS data provide a strong rationale for further investigation in larger, randomized phase 2 or 3 trials.
As the field of oncology moves further into the era of precision medicine, trials like IPATHER underscore the importance of molecular profiling even in well-established subtypes like HER2+ breast cancer. Future research should also explore whether similar benefits can be achieved with other AKT inhibitors or in different lines of therapy, as well as investigating the optimal management strategies for AKT-inhibitor-associated toxicities to ensure patient quality of life during extended maintenance therapy.
Funding and Clinical Trials
This study was supported by SOLTI and received funding and/or drug support from F. Hoffmann-La Roche/Genentech. ClinicalTrials.gov registration: NCT04253561.
References
Oliveira M, Ciruelos E, Villacampa G, et al. Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trial. Clin Cancer Res. 2025; doi: 10.1158/1078-0432.CCR-25-2298.